ketoprofen and Lymphedema

ketoprofen has been researched along with Lymphedema in 3 studies

Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.
ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.

Lymphedema: Edema due to obstruction of lymph vessels or disorders of the lymph nodes.

Research

Studies (3)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Part 1: Count of Participants Able to Complete Ketoprofen Treatment

Participants who were able to complete ketoprofen treatment and experienced no treatment-related serious adverse events. (NCT02257970)
Timeframe: Baseline to month 6

Part 2: Change From Baseline in Cutaneous Histological Architecture

Quantitative assessment of paired histological specimens of lymphedema skin pre- and post-treatment with ketoprofen. The impact of treatment on cutaneous histopathology was evaluated through the use of an empirically-derived scoring system (comprised of dermal thickness, intercellular mucin content, deep dermal collagen content, and perivascular infiltrate); this quantitative assessment was developed and performed by a dermatopathologist. Each characteristic was weighted equally and each specimen was assigned a cumulative subscale score of 0-5. The scores were summed for a total score (range: 0-20) which is presented here. Higher scores indicate a higher degree of pathology. A quantitatively higher negative change indicates a more favorable therapeutic response in the histology. (NCT02257970)
Timeframe: Baseline; Month 4

Part 2: Measurement of Skin Thickness

Caliper measured skin thickness (mm) of lymphedema-affected limb was serially assessed and pre-to-post paired analysis was performed. (NCT02257970)
Timeframe: Baseline and 4 months

Part 2/Part 3: Change From Baseline in Bioimpedance Spectroscopy

A four-electrode configuration was used to non-invasively assess the extracellular and intracellular fluid contents of the limb. Data were analyzed according to Cole theory, using the manufacturer's software (Impedimed Ltd.), to provide values for a bioimpedance ratio (Ro), the resistance of the extracellular fluid including lymph, R∞ the resistance of total tissue fluid and Ri, the resistance of the intracellular fluid. For the purposes of these investigations, in patients with unilateral lymphedema, the ratio of Ro in the affected:unaffected limbs was analyzed in each patient, as a measure of the bioimpedance attributable to the extracellular fluid content. An Ro level of 1.034 was considered normal; values ≥1.034 were considered abnormal. (NCT02257970)
Timeframe: Baseline; 4 months

Part 2/Part 3: Change in Limb Volume

Quantitative assessment of limb volume (ml) of the affected limb at study end compared to pre-treatment values. (NCT02257970)
Timeframe: Baseline; 4 months

Part 3: Change From Baseline in Cutaneous Histological Architecture

Quantitative assessment of paired histological specimens of lymphedema skin pre- and post-treatment with ketoprofen or placebo, respectively. The impact of treatment on cutaneous histopathology was evaluated through the use of an empirically-derived scoring system (comprised of dermal thickness, intercellular mucin content, deep dermal collagen content, and perivascular infiltrate); this quantitative assessment was developed and performed by a dermatopathologist. Each characteristic was weighted equally and each specimen was assigned a cumulative subscale score of 0-5. The scores were summed for a total score (range: 0-20) which is presented here. Higher scores indicate a higher degree of pathology. For the analysis, the 4-month post-minus-pre change in this score for ketoprofen- and placebo-recipients, respectively, was compared. A quantitatively higher negative change indicates a more favorable therapeutic response in the histology. (NCT02257970)
Timeframe: Baseline; 4 months

Part 3: Change in Systemic Inflammatory Mediator Granulocyte Colony Stimulating Factor (G-CSF)

The systemic inflammatory response of G-CSF, in the two treatment groups, Ketoprofen and Placebo, will be assessed with Luminex-bead inflammasome analysis of pre- and post-treatment plasma samples. G-CSF, a glycoprotein, is an inflammatory cytokine produced by endothelium and immune cells. Ketoprofen is a unique NSAID possessing dual pathways of inflammatory inhibition, blocking cyclooxygenase (COX) and 5-LO. Measurement using median fluorescence intensity (MFI) was employed. (NCT02257970)
Timeframe: Baseline; 4 months

Part 3: Measurement of Skin Thickness

Caliper-measured skin thickness (mm) was serially assessed and pre-to-post paired analysis was performed for both arms (Placebo and Ketoprofen) of the study. (NCT02257970)
Timeframe: Baseline and 4 months

Trials

1 trial available for ketoprofen and Lymphedema

Other Studies

2 other studies available for ketoprofen and Lymphedema